SN-38

DB05482InvestigationalSmall molecule

7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan DB00762, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used... SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negative Breast Cancer, among others.

Mechanism: The entrapment of SN-38 in lipsomes results in a more stable and more soluble form of the drug. This allows for increased affinity of SN-38 to lipid membranes and improved delivery of the drug to tumor sites. SN-38 is a highly effective cytotoxic topoisomerase I inhibitor.
Curator reviewed
Primary indication: Investigated for use/treatment in colorectal cancer.Curator reviewed
Formula / weight: C₂₂H₂₀N₂O₅ · 392.4046 g/mol (avg)
Also known as: 1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 4,11-DIETHYL-4,9-DIHYDROXY-, (4S)- · IRINOTECAN RELATED COMPOUND B
Code names: LE-SN38 · NK-012 · SN-38

Resolves to

Compound

UNII0H43101T0JCAS86639-52-3ChEMBLCHEMBL837ChEBI8988PubChem104842KEGGC11173

Structure

InChIKeyFJHBVJOVLFPMQE-QFIPXVFZSA-NSMILESCCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O

Targets

P11387TOP1

What you can answer from here — as of August 04, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

301Drug interactionsStructured to mechanism, not free text

21Clinical trialsPhase, status and sponsor resolved per trial

13+ReferencesStructured and connected to the statements they support

Which drugs share a target with SN-38, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account